JUPITER, Fla.--(BUSINESS WIRE)--BioCurity, a preclinical biotech company focused on developing novel mechanism-based nanoparticle drugs designed to transform radiation therapy for cancer patients worldwide, today announced the Company’s presentation at the American College of Radiation Oncology (ACRO) 2022 Summit on March 11, 2022, from 12:00-1:00pm EST at the Westin Fort Lauderdale Beach Resort in Fort Lauderdale, Florida. Details of the presentations are as follows:
Title: Harnessing Cerium Oxide Nanoparticles Combined with Tolfenamic Acid to Sensitize Head and Neck Cancer to Radiation
Session: Poster Walk with Professors - Bonnet
Presenter: Cheryl Baker, PhD, Scientific Co-Founder, BioCurity
The agenda for the ACRO 2022 Summit can be found here.
“Our IV and topical drug candidate consistent with positive preclinical data in lead indications such as head and neck, lung, and breast cancer was demonstrated to prevent radiation side effects without impairing the effectiveness of radiation killing cancer cells and shrinking tumors. BioCurity’s discovery could have a material positive impact for the millions of cancer patients that undergo radiation therapy annually. Approximately 70% of head and neck cancer patients treated with radiation therapy will develop severe oral mucositis, limiting their ability to eat or drink. We look forward to sharing our positive preclinical data with the leaders in radiation oncology at ACRO this week,” said Dr. Cheryl Baker, PhD, Scientific Co-Founder, and a Board Member of BioCurity.
About Cerium Oxide Nanoparticles
The production of hydrogen peroxide, a Reactive Oxygen Species (ROS) from radiation is a critical function for how radiation damages the DNA of cells of the tissue it passes through. BioCurity’s cerium oxide nanoparticles possess fast catalase activity in a normal tissue’s neutral pH environment and reduces radiation-induced hydrogen peroxide to molecular oxygen, thereby preventing radiation damage of normal tissue. BioCurity’s cerium oxide nanoparticles also possess superoxide dismutase activity in a cancerous tissue’s acidic pH environment and converts superoxide to hydrogen peroxide, thereby enhancing radiation-induced ROS damage of cancerous tissue.
BioCurity’s extensive preclinical studies in models of head and neck, lung, breast, pancreatic, prostate, and colorectal cancer show cerium oxide nanoparticles are regenerative and are not consumed in the reaction. Administration of cerium oxide nanoparticles at 1,000 times the effective dose did not produce toxicity in a small animal model.
About BioCurity
BioCurity Pharmaceuticals Inc. is a preclinical biotech company focused on developing novel mechanism-based nanoparticle drugs designed to transform radiation therapy for cancer patients worldwide. Approximately 50% of all cancer patients will receive radiation therapy at some point in their cancer treatment. With approximately 18 million new cancer patients a year globally, improving the outcome of radiation therapy is a world-unmet need. Fast track and orphan drug designations by the FDA for BioCurity’s drugs under development is possible. BioCurity is headquartered in Jupiter, Florida. For more information, please visit BioCurity’s website and follow BioCurity on LinkedIn, Facebook, Instagram, and Twitter.
This news release contains forward-looking statements, including those relating to the product development of BioCurity Pharmaceuticals Inc. (the "Company" or "BioCurity"), clinical and regulatory timelines, market opportunity and other statements that are predictive in nature, or that depend upon or refer to future events or conditions. Forward-looking statements may be identified by the use of forward-looking expressions, including, but not limited to, "expect," "anticipate," "intend," "plan," "believe," "estimate," "potential," "predict," "project," "should," "would" and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors, including the potential impact of the recent COVID-19 pandemic and the potential impact of sustained social distancing efforts, on our operations, clinical development plans and timelines, which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this news release. BioCurity's lead product candidate is in preclinical development and is not for sale or use. This news release is not an offer to buy any securities of the Company.
